Abstract:Objectives In order to investigate the effect of heat shock protein 90(HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin(17-AAG) in the implanted malignant pheochromocytoma nude mice and find the inhibitory mechanism of 17-AAG on the tumor growth and angiopoiesis of malignant pheochromocytoma.Methods We created the malignant pheochromocytoma xenograft model by implanting PC12 cells in the left flank of nude mice.After fifteen days,nude mice were randomly divided into two groups:the experiment group (receiving 17-AAG at dose of 40 mg/kg) and the control group (treated with NS at dose of 10 ml/kg).After three weeks' treatment,the tumors were obtained,then we measured the tumor volumes and weights in the fourth week.During this time,we observed the change of tumor volumes.The expressions of HSP90 and its client proteins signal transducers and activators of transcription3 (STAT3) 、human Epidermal Growth Factor Receptor.Results 2 (ERBB2) were detected by immunohistochemical staining and western blotting.In the fourth week,the tumor size in the experiment group is 2218.80 ± 336.29mm2,the weight is 7.94 ± 1.20g,while that in the control group is 5070.13 ± 630.42mm2,the weight is 3.29 ± 0.57g.A significant decrease of the size and weight of xenografts in the experiment group was observed as compared to those in the control group.The inhibitory rate of 17-AAG is 58.6％.The growth of tumor in the experiment group is slower than that in the control group,which has a statistical significance.The expressions of HSP90 、STAT3 and ERBB2 of tumor issues in the experiment group are each significantly lower than those in the control group(P ＜ 0.05).Conclusions 17-AAG has a significant effect on the transplanted pheochromocytoma in nude mice and suppresses the expression of HSP90 and STAT3 、ERBB2 in the tumor tissues.

The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model

The Effect of Inhibitor of Heat Shock Protein 90 on the Pheochromocytoma Xenograft Model

Effect of HSP90 Inhibitor in Pheochromocytoma PC12 Cells: an Experimental Investigation

Effects of 17-Allylamino-17-demethoxygeldanamycin on Apoptosis and Expression of Vascular Endothelial Growth Factor in Pheochromocytoma Cells

Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor

Synuclein Γ Protects Akt and Mtor and Renders Tumor Resistance to Hsp90 Disruption

The HSP90 Inhibitor 17-PAG Effectively Inhibits the Proliferation and Migration of Androgen-Independent Prostate Cancer Cells

HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma

HSP27 Expression Levels Are Associated with the Sensitivity of Hepatocellular Carcinoma Cells to 17-Allylamino-17-demethoxygeldanamycin.

Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells

Targeting Heat Shock Factor-1 by Shrna Interference:A Potential Tool to Enhances Therapeutic Efficiency of 17-Aag on Colon Cancer in Vitro

17-Abag, A Novel Geldanamycin Derivative, Inhibits Lncap-Cell Proliferation Through Heat Shock Protein 90 Inhibition

Influence of 17AAG on proliferation and invasion of gastric cancer cell and its mechanism

17-allylamino-17-demethoxygeldanamycin impeded chemotherapy through antioxidant activation via reducing reactive oxygen species-induced cell death.

Inhibitors of the HSP90 Molecular Chaperone: Current Status

Targeting Grp75 Improves Hsp90 Inhibitor Efficacy By Enhancing P53-Mediated Apoptosis In Hepatocellular Carcinoma

17-DMCHAG, a New Geldanamycin Derivative, Inhibits Prostate Cancer Cells Through Hsp90 Inhibition and Survivin Downregulation

Multiple Kinase Pathways Involved in the Different De Novo Sensitivity of Pancreatic Cancer Cell Lines to 17-AAG

Expression and Diagnostic Relevance of Heat Shock Protein 90 and Signal Transducer and Activator of Transcription 3 in Malignant Pheochromocytoma

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression

17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration